ReviewPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
Health inequities in pediatric anaphylaxis: A policy framework and call to action for equitable care from SIAIP allergy prevention commission.
Review in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Health inequities in pediatric anaphylaxis: A policy framework and call to action for equitable care from SIAIP allergy prevention commission.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric anaphylaxis is a rapidly evolving and potentially fatal allergic reaction whose incidence is increasing worldwide, particularly among young children. Despite international guidelines identifying intramuscular epinephrine as the first-line, life-saving treatment, significant health inequities persist in the prevention, recognition, and management of pediatric anaphylaxis. This manuscript, developed by the Primary and Secondary Prevention of Allergic Diseases Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP), moves beyond a traditional narrative review by integrating current evidence with a structured policy-oriented framework. Evidence highlights pronounced socioeconomic, racial, cultural, biological, and geographic inequities influencing disease burden, access to specialist care, prescription and availability of epinephrine autoinjectors (EAIs), training of caregivers and healthcare professionals, and timely epinephrine use in emergency settings. Building on this evidence, we propose a SIAIP-driven call to action and outline a preliminary national policy framework aimed at reducing inequities through coordinated interventions. Key priorities include equitable access to EAIs, standardized and repeated practical training, school-based preparedness programs, public awareness initiatives, integration of psychological support, and the development of national monitoring systems. By translating evidence into actionable strategies, this work provides a national perspective that complements existing international recommendations and offers a model for other countries seeking to address disparities in pediatric anaphylaxis care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.